ILM peeling beneficial, not harmful

Article

Peeling the internal limiting membrane (ILM) may reduce the rate of premacular fibrosis (PMF) formation, according to a study published in the June 2008 issue of Retina.

Peeling the internal limiting membrane (ILM) may reduce the rate of premacular fibrosis (PMF) formation, according to a study published in the June 2008 issue of Retina.

Ramin Schadlu, MD of the Department of Ophthalmology and Visual Science at Washington University of St Louis, US and colleagues conducted a retrospective chart review to establish the rate of favourable outcomes after surgical ILM peeling to remove PMF. Patients undergoing pars plana vitrectomy (PPV) and ILM peeling (n=38) had visual acuity assessed before and three months after surgery. Complications and PMF recurrence were noted.

Patients with higher presurgical visual acuity had the most favourable outcomes, with no adverse events and high postsurgical visual acuity. Following surgery, visual acuity remained the same or improved in 89.5% of treated eyes. Visual acuity improvement averaged 2.2 lines. PMF recurred in 2.6% of treated eyes (n=1). Cataract formation was the most common adverse event; following extraction, two patients developed cystoid macular oedema (CME).

The researchers concluded that the rate of adverse events associated with ILM peeling was not as high as previously believed and that, within this group of patients, outcomes were not unfavourable.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.